13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001512848
Total reported value
$1.6B
$1.6B
41 檔
42.6%
At the close of Q2 2024, NEA Management Company, LLC disclosed equity holdings valued at approximately $1.6B, spread across 41 reported holdings.
During Q2 2024, NEA Management Company, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 15.55% | -19.88% | EXIT | |
| 2 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 12.04% | — | — | |
| 3 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 8.99% | — | — | |
| 4 | SVRA | Savara Inc | Stock-Other | 7.42% | +1.89% | — | |
| 5 | COUR | Coursera Inc | Stock-Other | 6.93% | +0.31% | — | |
| 6 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 6.45% | +0.78% | — | |
| 7 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 6.08% | — | +9.32% | |
| 8 | NN | Nextnav Inc | Stock-Other | 5.00% | — | — | |
| 9 | KRRO | Korro Bio Inc | Stock-Other | 2.78% | +0.24% | +1.66% | |
| 10 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.55% | +6.56% | — | |
| 11 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.16% | +4.53% | — | |
| 12 | CVRX | Cvrx Inc | Stock-Other | 2.14% | -0.46% | — | |
| 13 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 1.71% | +0.90% | — | |
| 14 | NKTX | Nkarta Inc | Stock-Other | 1.59% | +0.21% | — | |
| 15 | BDTX | Black Diamond Therapeutics I | Stock-Other | 1.56% | -0.02% | — | |
| 16 | CELC | Celcuity Inc | Stock-Other | 1.54% | -3.56% | — | |
| 17 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.52% | +0.10% | — | |
| 18 | ADAPY | Adaptimmune Therapeutics-adr | Stock-Other | 1.25% | — | — | |
| 19 | GOSS | Gossamer Bio Inc | Stock-Other | 1.23% | -0.01% | +14.24% | |
| 20 | ✓ | Neuehealth Inc | Stock-Other | 1.12% | — | — | |
| 21 | GERN | Geron CORP | Stock-Other | 0.89% | — | -78.27% | |
| 22 | RGLSUSD | Regulus Therapeutics Inc | Stock-Other | 0.87% | — | — | |
| 23 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.82% | — | — | |
| 24 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.80% | -0.16% | — | |
| 25 | BZFD | Buzzfeed Inc | Stock-Other | 0.80% | — | — | |
| 26 | MYND | Mynd.ai Inc | Stock-Other | 0.76% | — | — | |
| 27 | CSBR | Champions Oncology Inc | Stock-Other | 0.67% | +0.10% | — | |
| 28 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.65% | +0.19% | — | |
| 29 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 0.54% | — | — | |
| 30 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 0.51% | — | — | |
| 31 | ALLKGUSD | Allakos Inc | Stock-Other | 0.46% | — | — | |
| 32 | DM* | Desktop Metal Inc-a | Stock-Other | 0.45% | — | — | |
| 33 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.44% | +0.03% | — | |
| 34 | TUYA | Tuya Inc | Stock-Other | 0.42% | — | -33.92% | |
| 35 | SYBX | Synlogic Inc | Stock-Other | 0.33% | — | — | |
| 36 | IVA | Inventiva SA - Adr | Stock-Other | 0.33% | -0.11% | — | |
| 37 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 0.30% | — | — | |
| 38 | ✓ | Affimed N V | Stock-Other | 0.18% | — | — | |
| 39 | ✓ | Senti Biosciences, Inc. | Stock-Other | 0.09% | — | — | |
| 40 | ✓ | Ikena Oncology Inc | Stock-Other | 0.07% | — | — | |
| 41 | 2CH | Wheels Up Experience Inc | Stock-Other | 0.02% | — | — |
According to official SEC Form 13F filings, NEA Management Company, LLC reported a total U.S. public equity portfolio value of $1.6B across 41 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, TEM, RYTM) accounted for 42.6% of total reported equity market value during Q2 2024.
During Q2 2024, NEA Management Company, LLC's top holdings by market value included ACLXGBX (15.6%)、TEM (12.0%)、RYTM (9.0%). The largest single position, ACLXGBX, represented 15.6% of total portfolio value.
In Q2 2024, NEA Management Company, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.